Andrew Advani

MD, FRCP, PhD, MBChB(Hons), BSc

Scientist, Keenan Research Centre for Biomedical Science


Dr. Andrew Advani is a Staff Endocrinologist and Associate Professor/Clinician Scientist at the Keenan Research Centre for Biomedical Science, St. Michael’s Hospital and Department of Medicine at University of Toronto. His research program is focused on the discovery and development of new treatments for diabetic kidney disease and related cardiovascular and kidney diseases.

Despite current treatments, people with diabetes continue to be affected by the long-term consequences of the disease. These long-term consequences include kidney disease, eye disease, nerve disease and heart disease. Kidney disease due to diabetes is the most common cause of kidney failure requiring treatment with dialysis or a kidney transplant and people with kidney disease are much more likely to die from heart disease. The Advani Lab is committed to conducting research on the causes of kidney disease in diabetes and on the links between kidney disease and heart disease. Through this research, Dr. Advani aims to develop new and better treatments for diabetes to reduce the burden of the condition on the millions of people affected.

Dr. Advani completed his medical training at the University of Edinburgh (UK) in 1996 and his PhD at Newcastle University (UK) in 2003. He was appointed on Staff at St. Michael’s Hospital in 2008. He is a Fellow of the Royal College of Physicians (UK). He has over 50 publications and has won awards from the British Hypertension Society, Royal College of Physicians (UK), Canadian Diabetes Association and Banting and Best Diabetes Centre. Research in the Advani Lab is supported by the Canadian Institutes of Health Research, Canadian Diabetes Association, Heart and Stroke Foundation of Canada and Kidney Foundation of Canada.

The Advani Lab is always interested in hearing from highly motivated and accomplished individuals interested in post-doctoral fellowships or graduate studentships.

Recent Publications

  1. Doria, A, Galecki, AT, Spino, C, Pop-Busui, R, Cherney, DZ, Lingvay, I et al.. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N. Engl. J. Med. 2020;382 (26):2493-2503. doi: 10.1056/NEJMoa1916624. PubMed PMID:32579810 .
  2. Abdalla, M, Abdalla, M, Siddiqi, FS, Geldenhuys, L, Batchu, SN, Tolosa, MF et al.. A common glomerular transcriptomic signature distinguishes diabetic kidney disease from other kidney diseases in humans and mice. Curr Res Transl Med. 2020; :. doi: 10.1016/j.retram.2020.05.001. PubMed PMID:32499177 .
  3. Mahmud, FH, Clarke, ABM, Joachim, KC, Assor, E, McDonald, C, Saibil, F et al.. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. Diabetes Care. 2020;43 (7):1553-1556. doi: 10.2337/dc19-1944. PubMed PMID:32345653 .
  4. Sanwal, R, Khosraviani, N, Advani, SL, Advani, A, Lee, WL. The Endothelial Barrier Is not Rate-limiting to Insulin Action in the Myocardium of Male Mice. Endocrinology. 2020;161 (4):. doi: 10.1210/endocr/bqaa029. PubMed PMID:32103251 PubMed Central PMC7069687.
  5. Connelly, KA, Zhang, Y, Desjardins, JF, Nghiem, L, Visram, A, Batchu, SN et al.. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19 (1):13. doi: 10.1186/s12933-020-0994-y. PubMed PMID:32035482 PubMed Central PMC7007658.
  6. Advani, A. Positioning time in range in diabetes management. Diabetologia. 2020;63 (2):242-252. doi: 10.1007/s00125-019-05027-0. PubMed PMID:31701199 .
  7. Majumder, S, Hadden, MJ, Thieme, K, Batchu, SN, Niveditha, D, Chowdhury, S et al.. Dysregulated expression but redundant function of the long non-coding RNA HOTAIR in diabetic kidney disease. Diabetologia. 2019;62 (11):2129-2142. doi: 10.1007/s00125-019-4967-1. PubMed PMID:31399844 .
  8. Markowitz, B, Pritlove, C, Mukerji, G, Lavery, JV, Parsons, JA, Advani, A et al.. The 3i Conceptual Framework for Recognizing Patient Perspectives of Type 1 Diabetes During Emerging Adulthood. JAMA Netw Open. 2019;2 (7):e196944. doi: 10.1001/jamanetworkopen.2019.6944. PubMed PMID:31298715 PubMed Central PMC6628591.
  9. Connelly, KA, Zhang, Y, Visram, A, Advani, A, Batchu, SN, Desjardins, JF et al.. Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2019;4 (1):27-37. doi: 10.1016/j.jacbts.2018.11.010. PubMed PMID:30847416 PubMed Central PMC6390677.
  10. Lytvyn, Y, Bjornstad, P, Lovshin, JA, Boulet, G, Farooqi, MA, Lai, V et al.. Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. Am. J. Kidney Dis. 2019;73 (6):786-796. doi: 10.1053/j.ajkd.2018.12.034. PubMed PMID:30799029 PubMed Central PMC7082148.
Search PubMed

Affiliations & Other Activities

  • Staff Endocrinologist/Clinician Scientist, Division of Endocrinology, St. Michael’s Hospital
  • Associate Professor/Clinician Scientist, Department of Medicine, University of Toronto